Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
In late October 2026, enterprise tech vendors converged on moving AI from experimentation to production. Fortinet, Cisco, ServiceNow, Intuit and Salesforce (buying Braze) launched security, governance, partner and customer-engagement products around AI agents. Meanwhile, Apple, NVIDIA, ASUS and Harvest Praxis pushed on-device and embodied AI hardware, and Encord's CEO argued that costly physical-AI data is the bottleneck. The fintech and finance angle is thin and indirect, limited to Intuit's accountant AI tools and a comment on AI paired with trusted financial infrastructure.
Late October to December 2026 brings a cluster of leadership handovers and board changes. Align Technology is the clearest case: Jennifer Davis is named CEO-elect and takes over on Dec 31, and Hogan retires from the board in June 2027. Oasis's two-nominee campaign at Vail Resorts adds activist pressure, ahead of the Dec 14 annual meeting. Other firms (Amgen, Coface, Bausch + Lomb, Odyssey, Econocom, NGEx) are making board appointments and calling shareholder votes. Alongside these, lawyer Seth Kugler argues that employees feeding confidential data into consumer AI tools creates trade-secret and contract exposure that boards and counsel now have to govern.
The 2026 ESMO Congress set off a burst of oncology readouts, launches and partnerships. Examples include ivonescimab's positive Phase III OS result in biliary tract cancer, Incyte's PDAC combinations with BMS and Synnovation, the US launch of ZEGFROVY, CLDN18.2 real-world evidence from Astellas, and Abbott's next-generation whole-genome MRD test. Alongside this, financially constrained small caps are retrenching. ADC Therapeutics is cutting its workforce for about $10M in annual savings, Spago is moving to delist from Nasdaq First North, and Akari is pushing its AKTX-101 trial start to mid-2027. The market is splitting into well-resourced players that turn data into launches and revenue, such as Novocure's record quarter, and sub-scale biotechs that conserve cash or exit public markets.
The AI buildup is driving record results and raised guidance across the semiconductor supply chain (Advanced Energy revenue up 64% YoY, Impinj's M800 strength, Penguin's raised fiscal 2027 outlook). Analysts such as Lynx Equity Strategies see 33–49% upside in memory names like Micron and Sandisk. Micron is also eligible to restart buybacks on 2026-12-09. Consolidation and capital-raising are underway (Kalray/Bull, SambaNova weighing a 2027 US IPO, Nvidia–SK Hynix expansion, Qorvo-style integration planning). Edge-AI launches (Zeta's AIM, Harvest Praxis with MediaTek, ASUS with NVIDIA RTX Spark) widen adoption. Longer-term themes include silicon photonics and advanced packaging for bandwidth and energy efficiency, and reversible-computing research (Hannah Earley) arguing waste heat is a design choice. Smaller defense-linked names like Solitron face slow procurement and a strategic review.
Fintech is moving toward 24/7 trading, event and KPI contracts, tokenized securities and AI-agent-driven commerce. Incumbents (Nasdaq, Cboe, Robinhood, LSEG) and regulators (CFTC, SEC, MiCA) are racing to shape the rules. Meanwhile, AI-focused startups such as Baselayer, PayOS and firmly are building identity, payment and fraud infrastructure for autonomous agents, and VCs like Norwest are funding the AI-native finance stack.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedStock market today: Dow, S&P 500, Nasdaq end little changed as strong jobs report complicates Fed's rate path
“Stock market today: Dow, S&P 500, Nasdaq end little changed as strong jobs report complicates Fed's rate path US stocks were little changed on Wednesday, as investors digested a January jobs report that blew past expectations on a monthly basis…”
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board
“Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Bo…”
Fluor Reports Fourth Quarter and Full Year 2025 Results
“Fluor Reports Fourth Quarter and Full Year 2025 Results Full year 2025 share repurchases of $754 million; $1.4 billion planned for 2026 Full year new awards of $12.0 billion; 87% reimbursable Ending Backlog of $25.5 billion; 81% reimbursable Received $1.35 billion in Q1 2026 for NuScale share sales IRVING, Texas, Febru…”
UBS declares coupon payments on 8 ETRACS Exchange Traded Notes
“UBS declares coupon payments on 8 ETRACS Exchange Traded Notes HDLB: linked to the Solactive US High Dividend Low Volatility Index SMHB: linked to the Solactive US Small Cap High Dividend Index PFFL: linked to the Solactive Preferred Stock ETF Index CEFD: linked to the S-Network Composite Closed-End Fund Index MVRL: li…”
Agero Enters into Agreement to Acquire Urgently, for $5.50 in Cash Per Share, Expanding Tech-Driven Roadside Assistance Across Automotive, Fleet, Rental, and Insurance Markets
“Agero Enters into Agreement to Acquire Urgently, for $5.50 in Cash Per Share, Expanding Tech-Driven Roadside Assistance Across Automotive, Fleet, Rental, and Insurance Markets MEDFORD, Mass…”
ChannelCon 2026 Registration Opens: “The Channel Effect” to Take Center Stage in San Diego August 3–5
“ChannelCon 2026 Registration Opens: “The Channel Effect” to Take Center Stage in San Diego August 3–5 OAKBROOK TERRACE, Ill., March 25, 2026 (GLOBE NEWSWIRE) -- Registration is now open for ChannelCon 2026, the Global Technology Industry Association (GTIA)’s premier annual event, which will take place August 3–5, 2026,…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Checked SEC filings show Micron's capital spending nearly doubled in a year and its cash reached $25.0 billion. Record results at smaller suppliers add to the picture. We also flag where the sources disagree and which have a weak track record.
Third-quarter calls from Lam Research, Dow and Union Pacific show two economies. AI-linked chip demand is outrunning supply, while chemicals and rail protect profit through cost cuts. Every figure is traced to a named speaker, an SEC filing or a source document.
Web Summit Lisbon's edition returns from 9 to 12 November, and the organisers' featured speakers page has a detail still rare at tech conferences: two of the "speakers" are robots.
Dow says its cost-cutting is ahead of schedule while its latest full-year results show the hole it is climbing out of. Union Pacific posted record profit and wants a merger. Both claims come from earnings calls, and the source's measured accuracy is 60%, so we separate what SEC filings confirm from what executives said.
Q3 2026 earnings calls show finance chiefs relying on cost cuts and cash cushions while energy costs stay high. Dow targets $1.3 billion of net benefits and Union Pacific's fuel price rose 64%. The figures come from earnings-call transcripts and SEC-checked filings; we flag where reporting is less certain.
Robinhood's checked SEC figures show revenue up about 2.4 times in two years and a swing from loss to profit. Now it is the first retail broker to offer Cboe's company-performance contracts, while startups raise money to prove AI agents can be trusted. Some of the evidence is thin, and we say where.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.